These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 11240690

  • 21. Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls.
    Paez CG, Yaegashi N, Sato S, Yajima A.
    Tohoku J Exp Med; 1993 Jun; 170(2):113-21. PubMed ID: 8266324
    [Abstract] [Full Text] [Related]

  • 22. Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA.
    Krchnák V, Vágner J, Suchánková A, Krcmár M, Ritterová L, Vonka V.
    J Gen Virol; 1990 Nov; 71 ( Pt 11)():2719-24. PubMed ID: 2174961
    [Abstract] [Full Text] [Related]

  • 23. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.
    Nonnenmacher B, Hubbert NL, Kirnbauer R, Shah KV, Muñoz N, Bosch FX, de Sanjosé S, Viscidi R, Lowy DR, Schiller JT.
    J Infect Dis; 1995 Jul; 172(1):19-24. PubMed ID: 7797910
    [Abstract] [Full Text] [Related]

  • 24. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia.
    Tjiong MY, van der Vange N, ter Schegget JS, Burger MP, ten Kate FW, Out TA.
    Cytokine; 2001 Jun 21; 14(6):357-60. PubMed ID: 11497498
    [Abstract] [Full Text] [Related]

  • 25. Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer.
    Müller M, Viscidi RP, Sun Y, Guerrero E, Hill PM, Shah F, Bosch FX, Muñoz N, Gissmann L, Shah KV.
    Virology; 1992 Apr 21; 187(2):508-14. PubMed ID: 1312268
    [Abstract] [Full Text] [Related]

  • 26. Independent association of antibodies against human papillomavirus type 16 E1/E4 and E7 proteins with cervical cancer.
    Kanda T, Onda T, Zanma S, Yasugi T, Furuno A, Watanabe S, Kawana T, Sugase M, Ueda K, Sonoda T.
    Virology; 1992 Oct 21; 190(2):724-32. PubMed ID: 1325704
    [Abstract] [Full Text] [Related]

  • 27. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations.
    Nindl I, Zumbach K, Pawlita M, Teller K, Schneider A, Dürst M.
    J Infect Dis; 2000 May 21; 181(5):1764-7. PubMed ID: 10783118
    [Abstract] [Full Text] [Related]

  • 28. Major sequence variants in E7 gene of human papillomavirus type 16 from cervical cancerous and noncancerous lesions of Korean women.
    Song YS, Kee SH, Kim JW, Park NH, Kang SB, Chang WH, Lee HP.
    Gynecol Oncol; 1997 Aug 21; 66(2):275-81. PubMed ID: 9264576
    [Abstract] [Full Text] [Related]

  • 29. Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer.
    Dillner L, Zellbi A, Avall-Lundqvist E, Heino P, Eklund C, Pettersson CA, Forslund O, Hansson BG, Grandien M, Bistoletti P.
    Cancer Detect Prev; 1995 Aug 21; 19(5):381-93. PubMed ID: 7585724
    [Abstract] [Full Text] [Related]

  • 30. High prevalence of serum antibodies to Ras and type 16 E4 proteins of human papillomavirus in patients with precancerous lesions of the uterine cervix.
    Pedroza-Saavedra A, Cruz A, Esquivel F, De La Torre F, Berumen J, Gariglio P, Gutiérrez L.
    Arch Virol; 2000 Aug 21; 145(3):603-23. PubMed ID: 10795526
    [Abstract] [Full Text] [Related]

  • 31. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
    Liu TY, Xie R, Luo L, Reilly KH, He C, Lin YZ, Chen G, Zheng XW, Zhang LL, Wang HB.
    J Virol Methods; 2014 Feb 21; 196():120-5. PubMed ID: 24216236
    [Abstract] [Full Text] [Related]

  • 32. Detection of Immunoglobulin G against E7 of Human Papillomavirus in Non-Small-Cell Lung Cancer.
    Storey R, Joh J, Kwon A, Jenson AB, Ghim SJ, Kloecker GH.
    J Oncol; 2013 Feb 21; 2013():240164. PubMed ID: 23533408
    [Abstract] [Full Text] [Related]

  • 33. Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions.
    Lazarenko LM, Nikitina OE, Nikitin EV, Demchenko OM, Kovtonyuk GV, Ganova LO, Bubnov RV, Shevchuk VO, Nastradina NM, Bila VV, Spivak MY.
    EPMA J; 2014 Jan 06; 5(1):1. PubMed ID: 24386936
    [Abstract] [Full Text] [Related]

  • 34. The Role of the Cervicovaginal and Gut Microbiome in Cervical Intraepithelial Neoplasia and Cervical Cancer.
    Sims TT, Colbert LE, Klopp AH.
    J Immunother Precis Oncol; 2021 May 06; 4(2):72-78. PubMed ID: 35663536
    [Abstract] [Full Text] [Related]

  • 35. Relationship between Human Papillomavirus Status and the Cervicovaginal Microbiome in Cervical Cancer.
    Nguyen HDT, Le TM, Lee E, Lee D, Choi Y, Cho J, Park NJ, Chong GO, Seo I, Han HS.
    Microorganisms; 2023 May 27; 11(6):. PubMed ID: 37374919
    [Abstract] [Full Text] [Related]

  • 36. Recurrent cervical cancer detection using DNA methylation markers in self-collected samples from home.
    Schaafsma M, van den Helder R, Mom CH, Steenbergen RDM, Bleeker MCG, van Trommel NE.
    Int J Cancer; 2024 Aug 22. PubMed ID: 39175103
    [Abstract] [Full Text] [Related]

  • 37. Cervicovaginal Microbiome Factors in Clearance of Human Papillomavirus Infection.
    Dai W, Du H, Li S, Wu R.
    Front Oncol; 2021 Aug 22; 11():722639. PubMed ID: 34395294
    [Abstract] [Full Text] [Related]

  • 38. Cervicovaginal microbiota: a promising direction for prevention and treatment in cervical cancer.
    Shen J, Sun H, Chu J, Gong X, Liu X.
    Infect Agent Cancer; 2024 Apr 19; 19(1):13. PubMed ID: 38641803
    [Abstract] [Full Text] [Related]

  • 39. IPA Analysis of Cervicovaginal Fluid from Precancerous Women Points to the Presence of Biomarkers for the Precancerous State of Cervical Carcinoma.
    Van Ostade X, Dom M, Van Raemdonck G.
    Proteomes; 2014 Aug 13; 2(3):426-450. PubMed ID: 28250389
    [Abstract] [Full Text] [Related]

  • 40. Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment.
    Łaniewski P, Cui H, Roe DJ, Chase DM, Herbst-Kralovetz MM.
    NPJ Precis Oncol; 2020 Aug 13; 4():22. PubMed ID: 32802959
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.